Malignant Pleural Mesothelioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: MLG079 MIFTS: 44	Malignant Pleural Mesothelioma Categories: Cancer diseases, Respiratory diseases
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Malignant Pleural Mesothelioma

MalaCards integrated aliases for Malignant Pleural Mesothelioma:

Name: Malignant Pleural Mesothelioma ¹² ³⁷ ¹⁵ ⁷³

Malignant Mesothelioma of Pleura ¹²

Pleural Malignant Mesothelioma ⁵⁵

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Respiratory diseases

See all MalaCards categories (disease lists)

ICD10: ³³

Neoplasms

Malignant neoplasms of mesothelial and soft tissue

Mesothelioma

Mesothelioma of pleura

External Ids:

Disease Ontology ¹² DOID:7474

ICD10 ³³ C45.0

NCIt ⁵⁰ C7376

KEGG ³⁷ H00015

UMLS ⁷³ C0812413

Sources

Summaries for Malignant Pleural Mesothelioma

Disease Ontology : ¹² A pleural cancer that has material basis in mesothelium cells.

MalaCards based summary : Malignant Pleural Mesothelioma, also known as malignant mesothelioma of pleura, is related to mesothelioma, malignant and pleural disease, and has symptoms including fatigue, dyspnea and chest pain. An important gene associated with Malignant Pleural Mesothelioma is PVT1 (Pvt1 Oncogene). The drugs Alimta and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include lung, t cells and endothelial, and related phenotype is normal.

Sources

Related Diseases for Malignant Pleural Mesothelioma

Diseases in the Benign Pleural Mesothelioma family:

Malignant Pleural Mesothelioma

Diseases related to Malignant Pleural Mesothelioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 113)

#	Related Disease	Score	Top Affiliating Genes
1	mesothelioma, malignant	31.4	BAP1 CALB2 MET MSLN MUC1 NKX2-1
2	pleural disease	30.6	BAP1 CALB2 MSLN SPP1
3	sarcoma, synovial	30.2	CALB2 MET MUC1
4	lung cancer susceptibility 3	30.1	BIRC5 CALB2 GAS5 MET MSLN MUC1
5	sarcomatoid mesothelioma	30.1	NKX2-1 THBD WT1
6	lung cancer	30.0	BIRC5 GAS5 MET NKX2-1 PVT1 SNHG7
7	renal cell carcinoma, nonpapillary	29.7	GAS5 MET MUC1 NKX2-1 PVT1 WT1
8	pancreatic cancer	29.6	BIRC5 ENSG00000261211 GAS5 MET MSLN MUC1
9	benign mesothelioma	11.2
10	adenocarcinoma	10.4
11	fallopian tube carcinosarcoma	10.3	CALB2 WT1
12	ovarian serous cystadenofibroma	10.3	CALB2 MUC1
13	adenofibroma	10.3	CALB2 MUC1
14	malignant peritoneal mesothelioma	10.3	BIRC5 MUC1
15	small cell cancer of the lung	10.2
16	solid adenocarcinoma with mucin production	10.2	MUC1 NKX2-1
17	peritoneal benign neoplasm	10.2	CALB2 WT1
18	bile duct cystadenocarcinoma	10.2	CALB2 MUC1
19	endosalpingiosis	10.2	MUC1 WT1
20	diffuse peritoneal leiomyomatosis	10.2	CALB2 WT1
21	ovarian small cell carcinoma	10.2	MUC1 WT1
22	venous hemangioma	10.2	CALB2 WT1
23	malignant epithelial mesothelioma	10.2	THBD WT1
24	mucinous bronchioloalveolar adenocarcinoma	10.2	CALB2 MUC1 NKX2-1
25	lymphohistiocytoid mesothelioma	10.2	CALB2 THBD
26	sertoli cell tumor	10.2	CALB2 MUC1 WT1
27	rhabdoid tumor predisposition syndrome 1	10.2	MUC1 SPP1 WT1
28	malignant ovarian surface epithelial-stromal neoplasm	10.2	MSLN MUC1 WT1
29	chordoid glioma	10.2	MUC1 NKX2-1
30	ovary epithelial cancer	10.2	MSLN MUC1 WT1
31	sertoli-leydig cell tumor	10.2	CALB2 MUC1 WT1
32	osteofibrous dysplasia	10.2	MET MUC1 SPP1
33	thymus cancer	10.2	CALB2 MUC1 NKX2-1
34	pneumothorax, primary spontaneous	10.2
35	patulous eustachian tube	10.2
36	pneumothorax	10.2
37	squamous cell carcinoma	10.2
38	hypoxia	10.2
39	pericardium cancer	10.2	CALB2 MSLN THBD
40	mixed germ cell-sex cord neoplasm	10.2	CALB2 WT1
41	desmoplastic small round cell tumor	10.2	MUC1 WT1
42	rete testis adenocarcinoma	10.2	CALB2 NKX2-1 THBD
43	rete testis neoplasm	10.2	CALB2 NKX2-1 THBD
44	papillary carcinoma	10.2	MET MUC1 NKX2-1
45	mucinous ovarian cystadenoma	10.1	CALB2 MUC1
46	ovarian brenner tumor	10.1	CALB2 THBD WT1
47	spindle cell liposarcoma	10.1	CALB2 WT1
48	pancreas adenocarcinoma	10.1	MET MSLN MUC1
49	malignant biphasic mesothelioma	10.1	CALB2 MSLN THBD WT1
50	thyroid cancer, nonmedullary, 1	10.1	GAS5 NKX2-1 PVT1

Graphical network of the top 20 diseases related to Malignant Pleural Mesothelioma:

Sources

Symptoms & Phenotypes for Malignant Pleural Mesothelioma

UMLS symptoms related to Malignant Pleural Mesothelioma:

fatigue, dyspnea, chest pain, chills, malaise

MGI Mouse Phenotypes related to Malignant Pleural Mesothelioma:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	9.23	BIRC5 CALB2 MET MSLN NKX2-1 THBD

Sources

Drugs & Therapeutics for Malignant Pleural Mesothelioma

FDA approved drugs:

#	Drug Name	Active Ingredient(s) ¹⁸	Company	Approval Date
1	Alimta ¹⁸ ⁴⁹	PEMETREXED (also Pemetrexed Disodium)	Eli Lilly	February 2004
FDA Label: Alimta Disease/s that Drug Treats:Mesothelioma Indications and Usage: ¹⁸ ALIMTAÂ® is a folate analog metabolic inhibitor indicated for: Locally Advanced or Metastatic Nonsquamous Non-Small CellLung Cancer: Initial treatment in combination with cisplatin. (1.1) Maintenance treatment of patients whose disease has notprogressed after four cycles of platinum-based first-linechemotherapy. (1.2) After prior chemotherapy as a single-agent. (1.3) Mesothelioma: in combination with cisplatin. (1.4)Limitations of Use: ALIMTA is not indicated for the treatment of patients withsquamous cell non-small cell lung cancer. (1.5) DrugBank Targets: ¹⁶ 1. Thymidylate synthase;2. Bifunctional purine biosynthesis protein PURH;3. Dihydrofolate reductase;4. Trifunctional purine biosynthetic protein adenosine-3 Mechanism of Action: ¹⁸ Target: folic acid/ thymidylate synthase, dihydrofolate reductase, and glycinamide ribonucleotide formyltransferase Action: antagonist/ inhibitor FDA: ALIMTA, pemetrexed for injection, is a folate analog metabolic inhibitor that exerts its action by disrupting folatedependentmetabolic processes essential for cell replication. In vitro studies have shown that pemetrexed inhibitsthymidylate synthase (TS), dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT),which are folate-dependent enzymes involved in the de novo biosynthesis of thymidine and purine nucleotides.Pemetrexed is taken into cells by membrane carriers such as the reduced folate carrier and membrane folate bindingprotein transport systems. Once in the cell, pemetrexed is converted to polyglutamate forms by the enzymefolylpolyglutamate synthetase. The polyglutamate forms are retained in cells and are inhibitors of TS and GARFT.Polyglutamation is a time- and concentration-dependent process that occurs in tumor cells and, is thought to occur to alesser extent, in normal tissues. Polyglutamated metabolites are thought to have an increased intracellular half-liferesulting in prolonged drug action in malignant cells.

Drugs for Malignant Pleural Mesothelioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 186)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Pemetrexed

Approved, Investigational

Phase 3,Phase 2,Phase 1,Not Applicable

150399-23-8, 137281-23-3

446556 60843

Gemcitabine

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

95058-81-4

60750

Doxorubicin

Approved, Investigational

Phase 3,Phase 2

23214-92-8

31703

Vinorelbine

Approved, Investigational

Phase 3,Phase 2,Phase 1

71486-22-1

60780 44424639

Cisplatin

Approved

Phase 3,Phase 2,Phase 1

15663-27-1

2767 441203 84093

leucovorin

Approved

Phase 3,Phase 2,Phase 1,Not Applicable

58-05-9

6006 143

Hydroxocobalamin

Approved

Phase 2, Phase 3,Phase 3

13422-51-0

11953898 44475014

Methylcobalamin

Approved, Experimental, Investigational

Phase 2, Phase 3,Phase 3

13422-55-4

Dexamethasone acetate

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Phase 1

1177-87-3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 3,Phase 2,Phase 1

50-02-2

5743

Vinblastine

Approved

Phase 3,Phase 2,Phase 1

865-21-4

241903 13342

Vorinostat

Approved, Investigational

Phase 3,Phase 1,Phase 2

149647-78-9

5311

Vincristine

Approved, Investigational

Phase 3

57-22-7, 2068-78-2

5978

Raltitrexed

Approved, Investigational

Phase 3,Phase 1,Phase 2

112887-68-0

104758

Nintedanib

Approved

Phase 3,Phase 2

656247-17-5

56843413

Bevacizumab

Approved, Investigational

Phase 2, Phase 3,Phase 1

216974-75-3

Carboplatin

Approved

Phase 3,Phase 2,Phase 1

41575-94-4

10339178 38904 498142

Nivolumab

Approved

Phase 3,Phase 2

946414-94-4

Celecoxib

Approved, Investigational

Phase 3,Phase 1,Phase 2

169590-42-5

2662

Pembrolizumab

Approved

Phase 2, Phase 3,Phase 3,Phase 1

1374853-91-4

Folic Acid

Approved, Nutraceutical, Vet_approved

Phase 3,Phase 2,Phase 1,Not Applicable

59-30-3

6037

Cyanocobalamin

Approved, Nutraceutical

Phase 2, Phase 3,Phase 3

68-19-9

44176380

Doxil

Approved June 1999

Phase 3,Phase 2

31703

Cobalamin

Experimental

Phase 2, Phase 3,Phase 3

13408-78-1

6438156

Antibiotics, Antitubercular

Phase 3,Phase 2,Phase 1

Anti-Bacterial Agents

Phase 3,Phase 2,Phase 1

Antiemetics

Phase 3,Phase 2,Phase 1

Antimitotic Agents

Phase 3,Phase 2,Phase 1

Antineoplastic Agents, Phytogenic

Phase 3,Phase 2,Phase 1

Alkylating Agents

Phase 3,Phase 1,Phase 2

Nucleic Acid Synthesis Inhibitors

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B9

Phase 3,Phase 2,Phase 1,Not Applicable

Folate

Phase 3,Phase 2,Phase 1,Not Applicable

Folic Acid Antagonists

Phase 3,Phase 2,Phase 1,Not Applicable

Vitamin B Complex

Phase 3,Phase 2,Phase 1,Not Applicable

Antimetabolites, Antineoplastic

Phase 3,Phase 2,Phase 1

Antimetabolites

Phase 3,Phase 2,Phase 1

Vitamins

Phase 2, Phase 3,Phase 3

Vitamin B 12

Phase 2, Phase 3,Phase 3

Vitamin B12

Phase 2, Phase 3,Phase 3

Micronutrients

Phase 3,Phase 2

Autonomic Agents

Phase 3,Phase 2,Phase 1

Peripheral Nervous System Agents

Phase 3,Phase 2,Phase 1

Gastrointestinal Agents

Phase 3,Phase 2,Phase 1

BB 1101

Phase 3,Phase 2,Phase 1

Trace Elements

Phase 3,Phase 2

Antiviral Agents

Phase 3,Phase 2,Phase 1

Immunoglobulins

Phase 3,Phase 2,Phase 1

Immunosuppressive Agents

Phase 3,Phase 2,Phase 1

Antibodies

Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 201)

#	Name	Status	NCT ID	Phase	Drugs
1	NGR015: Study in Second Line for Patient With Advanced Malignant Pleural Mesothelioma Pretreated With Pemetrexed	Completed	NCT01098266	Phase 3	NGR-hTNF plus Best Investigator's Choice (BIC);Placebo plus Best Investigator's Choice (BIC)
2	Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) Versus Placebo in Advanced Malignant Pleural Mesothelioma (0683-014 AM5, EXT1)	Completed	NCT00128102	Phase 3	vorinostat;Placebo
3	Active Symptom Control With or Without Chemotherapy in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00075699	Phase 3	cisplatin;mitomycin C;vincristine sulfate;vinorelbine tartrate
4	Cisplatin With or Without Pemetrexed Disodium in Treating Patients With Malignant Mesothelioma of the Pleura That Cannot be Removed by Surgery	Completed	NCT00005636	Phase 3	cisplatin;pemetrexed disodium
5	Cisplatin With or Without Raltitrexed in Treating Patients With Malignant Mesothelioma of the Pleura	Completed	NCT00004920	Phase 3	cisplatin;raltitrexed
6	Nintedanib (BIBF 1120) in Mesothelioma	Completed	NCT01907100	Phase 3	Nintedanib;Pemetrexed;Cisplatin;Cisplatin;Pemetrexed;Placebo
7	A Study Comparing Pemetrexed Plus Best Supportive Care Versus Best Supportive Care Alone in the Treatment of Mesothelioma	Completed	NCT00190762	Phase 3	Pemetrexed
8	Mesothelioma Avastin Plus Pemetrexed-cisplatin Study	Completed	NCT00651456	Phase 2, Phase 3	Standard Chemotherapy (Pemetrexed and Cisplatin);Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab
9	Alimta® Versus Its Combination With Carboplatin in Advanced Non-small-cell Lung Cancer in Patients Performance Status 2	Completed	NCT01836575	Phase 3	Pemetrexed;Carboplatin
10	Ph 2/3 Study in Subjects With MPM w/Low ASS 1 Expression to Assess ADI-PEG 20 With Pemetrexed and Cisplatin	Recruiting	NCT02709512	Phase 2, Phase 3	ADI-PEG 20 plus Pem Cis
11	Pembrolizumab in Patients With Advanced Malignant Pleural Mesothelioma	Recruiting	NCT02784171	Phase 2, Phase 3	Cisplatin;Pemetrexed;Pembrolizumab
12	PembROlizuMab Immunotherapy Versus Standard Chemotherapy for Advanced prE-treated Malignant Pleural Mesothelioma	Active, not recruiting	NCT02991482	Phase 3	Pembrolizumab;Gemcitabine;Vinorelbine
13	Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients	Active, not recruiting	NCT02899299	Phase 3	Pemetrexed;Cisplatin;Carboplatin
14	Efficacy & Safety of rAd-IFN Administered With Celecoxib & Gemcitabine in Patients With Malignant Pleural Mesothelioma	Not yet recruiting	NCT03710876	Phase 3	Celecoxib Oral Product;Gemcitabine
15	BEAT-meso: Bevacizumab and Atezolizumab in Malignant Pleural Mesothelioma	Not yet recruiting	NCT03762018	Phase 3	Carboplatin;Pemetrexed;Bevacizumab;Atezolizumab
16	PIT: Prophylactic Irradiation of Tracts in Patients With Malignant Pleural Mesothelioma	Terminated	NCT01604005	Phase 3
17	A Clinical Trial of ADI-PEG 20TM in Patients With Malignant Pleural Mesothelioma	Unknown status	NCT01279967	Phase 2	ADI-PEG 20
18	Palliative Treatment With Liposomal Doxorubicin Plus Cisplatin for Patients With Malignant Pleural Mesothelioma	Unknown status	NCT00886028	Phase 2	Liposomal doxorubicin;Cisplatin
19	Trimodal Lung-Sparing Treatment of Pleural Mesothelioma	Unknown status	NCT00859495	Phase 2	Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)
20	Four Versus Six Cycles of Pemetrexed/Platinum for MPM	Unknown status	NCT02497053	Phase 2	pemetrexed/platinum chemotherapy;Pemetrexed/platinum chemotherapy
21	Combination Gene Transfer and Chemotherapy	Unknown status	NCT01119664	Phase 1, Phase 2	SCH 721015
22	Combination Chemotherapy With or Without Surgery and Chemoradiotherapy in Treating Patients With Malignant Pleural Mesothelioma	Unknown status	NCT00354393	Phase 2	cisplatin;methotrexate;vinorelbine ditartrate
23	MPM PDT Phase II Trial	Unknown status	NCT02153229	Phase 2	Photofrin 2.0 mg/kg
24	A Phase II Trial to Assess TroVax® Plus Chemotherapy in Patients With Malignant Pleural Mesothelioma	Unknown status	NCT01569919	Phase 2	Pemetrexed;Cisplatin;Dexamethasone
25	A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)	Unknown status	NCT02588131	Phase 2	tremelimumab plus MEDI4736
26	A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma	Unknown status	NCT01649024	Phase 2	Tremelimumab
27	The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma	Unknown status	NCT01655888	Phase 2	Tremelimumab
28	Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma	Unknown status	NCT00996385	Phase 2	Velcade (bortezomib) plus Eloxatin (oxaliplatin)
29	Cisplatin With Alimta or Gemcitabine in Long Infusion for Mesothelioma	Unknown status	NCT01281800	Phase 2
30	SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma	Unknown status	NCT01362790	Phase 1, Phase 2	Pentostatin;Cyclophosphamide
31	Intrapleural Administration of HSV1716 to Treat Patients With Malignant Pleural Mesothelioma.	Completed	NCT01721018	Phase 1, Phase 2
32	Safety Confirmation Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Completed	NCT00386815	Phase 2	pemetrexed;cisplatin
33	Gemcitabine in Long Infusion and Cisplatin for Malignant Pleural Mesothelioma Treatment	Completed	NCT01243632	Phase 2	Prolonged 6-hr infusion of gemcitabine
34	A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma	Completed	NCT01486368	Phase 2	PF-03446962
35	Study of NGR-hTNF as Single Agent in Patients Affected by Advanced or Metastatic Malignant Pleural Mesothelioma	Completed	NCT00484276	Phase 2	NGR-hTNF
36	Safety and Efficacy of TTFields (150 kHz) Concomitant With Pemetrexed and Cisplatin or Carboplatin in Malignant Pleural Mesothelioma (STELLAR)	Completed	NCT02397928	Phase 2	Pemetrexed;Cisplatin or Carboplatin
37	Everolimus (RAD001) for the Treatment of Malignant Pleural Mesothelioma With Merlin/NF2 Loss as a Biomarker to Predict Sensitivity	Completed	NCT01024946	Phase 2	everolimus
38	Study of Carboplatin and Vinorelbine in Malignant Pleural Mesothelioma	Completed	NCT00272558	Phase 2	Carboplatin and Vinorelbine
39	Intrapleural Photodynamic Therapy in a Multimodal Treatment for Patients With Malignant Pleural Mesothelioma	Completed	NCT02662504	Phase 2	Adjuvant chemotherapy
40	A Study of BBI608 in Combination With Pemetrexed and Cisplatin in Adult Patients With Malignant Pleural Mesothelioma	Completed	NCT02347917	Phase 1, Phase 2	BBI608;Pemetrexed;Cisplatin
41	WT-1 Analog Peptide Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy	Completed	NCT01265433	Phase 2
42	Study of CBP501 + Pemetrexed + Cisplatin on MPM (Phase I/II)	Completed	NCT00700336	Phase 1, Phase 2	pemetrexed, cisplatin and CBP501;pemetrexed and cisplatin
43	Anti-TGF Monoclonal Antibody (GC1008) in Relapsed Malignant Pleural Mesothelioma	Completed	NCT01112293	Phase 2	GC1008
44	Phase II Study of NGR-hTNF Versus Placebo as Maintenance Treatment in Patients With Advanced MPM	Completed	NCT01358084	Phase 2	NGR-hTNF;Placebo
45	Pazopanib in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00459862	Phase 2	pazopanib hydrochloride
46	Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma	Completed	NCT00251550	Phase 1, Phase 2	Pemetrexed;Cisplatin
47	Bortezomib in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00513877	Phase 2	bortezomib
48	S0509 - AZD2171 in Treating Patients With Malignant Pleural Mesothelioma That Cannot Be Removed By Surgery	Completed	NCT00243074	Phase 2	cediranib maleate
49	An Efficacy Study of MORAb-009 (Amatuximab) in Subjects With Pleural Mesothelioma	Completed	NCT00738582	Phase 2	MORAb-009 (Amatuximab);Pemetrexed;Cisplatin
50	Pemetrexed Disodium and Cisplatin Followed By Surgery and Radiation Therapy in Treating Patients With Malignant Pleural Mesothelioma	Completed	NCT00227630	Phase 2	cisplatin;pemetrexed disodium

Search NIH Clinical Center for Malignant Pleural Mesothelioma

Sources

Genetic Tests for Malignant Pleural Mesothelioma

Sources

Anatomical Context for Malignant Pleural Mesothelioma

MalaCards organs/tissues related to Malignant Pleural Mesothelioma:

⁴¹

Lung, T Cells, Endothelial, Thymus, Testes, Liver, Kidney

Sources

Publications for Malignant Pleural Mesothelioma

Articles related to Malignant Pleural Mesothelioma:

(show top 50) (show all 1375)

#	Title	Authors	Year
1	Simultaneous presence of lung adenocarcinoma and malignant pleural mesothelioma: A case report. ( 30533375 )	Yamazoe M...Katsuyama E	2019
2	Correction: Apoptosis by [Pt(O,O'-acac)(I^-acac)(DMS)] requires PKC-I' mediated p53 activation in malignant pleural mesothelioma. ( 29432478 )	Muscella A....Marsigliante S.	2018
3	Expression analysis of High-mobility group box-1 (HMGB1) in histologic samples of malignant pleural mesothelioma. ( 29356044 )	Rrapaj E....Boldorini R.L.	2018
4	Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma. ( 29362358 )	Sato H....Toyooka S.	2018
5	British Thoracic Society Guideline for the investigation and management of malignant pleural mesothelioma. ( 29444986 )	Woolhouse I....Maskell N.A.	2018
6	Assessment of new HDAC inhibitors for immunotherapy of malignant pleural mesothelioma. ( 29946373 )	Bensaid D....Blanquart C.	2018
7	PD-1 blockade with nivolumab in patients with recurrent Malignant Pleural Mesothelioma. ( 29908324 )	Quispel-Janssen J....Baas P.	2018
8	Dynamic contrast-enhanced CT for the assessment of tumour response in malignant pleural mesothelioma: a pilot study. ( 29967955 )	Gudmundsson E....Armato S.G.	2018
9	Current surgical treatment of malignant pleural mesothelioma. ( 29980443 )	Chihara K.	2018
10	Prostate-specific membrane antigen avidity on positron emission tomography scan in malignant pleural mesothelioma. ( 29873168 )	Ekanayake S.K.D.M....Lee J.C.	2018
11	Multiple intracranial metastases from postoperative giant sarcomatoid malignant pleural mesothelioma: A case report and literature review. ( 29387394 )	Tian D....Fu M.	2018
12	Radical multimodality therapy for malignant pleural mesothelioma. ( 29309720 )	Abdel-Rahman O....Eltobgy M.	2018
13	An RNAi-based screen reveals PLK1, CDK1 and NDC80 as potential therapeutic targets in malignant pleural mesothelioma. ( 29438360 )	Linton A....Reid G.	2018
14	FDG PET-derived parameters as prognostic tool in progressive malignant pleural mesothelioma treated patients. ( 29876617 )	Incerti E....Picchio M.	2018
15	Biomarkers in malignant pleural mesothelioma: current status and future directions. ( 29850181 )	Ahmadzada T....Kao S.	2018
16	Computed tomography in the evaluation of malignant pleural mesothelioma-Association of tumor size to a sarcomatoid histology, a more advanced TNM stage and poor survival. ( 29413055 )	Paajanen J....Vehmas T.	2018
17	A Phase II Trial of First-Line Combination Chemotherapy With Cisplatin, Pemetrexed, and Nivolumab for Unresectable Malignant Pleural Mesothelioma: A Study Protocol. ( 29853412 )	Fujimoto N....Hotta K.	2018
18	Critical role of the Ror-family of receptor tyrosine kinases in invasion and proliferation of malignant pleural mesothelioma cells. ( 29845703 )	Saji T....Minami Y.	2018
19	Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma. ( 29931180 )	Gill R.R....Richards W.G.	2018
20	Heterogeneity in Malignant Pleural Mesothelioma. ( 29848954 )	Oehl K....Meerang M.	2018
21	Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. ( 29346042 )	Kindler H.L....Hassan R.	2018
22	Biomarker-Integrated Neoadjuvant Dasatinib Trial in Resectable Malignant Pleural Mesothelioma. ( 29313814 )	Tsao A.S....Hong W.K.	2018
23	Biomarkers for Early Diagnosis and Prognosis of Malignant Pleural Mesothelioma: The Quest Goes on. ( 29914087 )	Ledda C....Rapisarda V.	2018
24	The management of malignant pleural mesothelioma in the USA 2004-13-a decade of lost opportunity? ( 29849196 )	Waller D.A.	2018
25	Clinical evaluation of circulating miR-548a-3p and -20a expression in malignant pleural mesothelioma patients. ( 29338319 )	Matboli M....Abdel-Rahman O.	2018
26	Variation in incidence trends of malignant pleural mesothelioma in Europe. ( 29437947 )	Ahmed M....Breen D.	2018
27	Malignant Pleural Mesothelioma: The Last 8 Years of Experience in Our Area. ( 29804950 )	BenA-tez J.C....BastA_s R.	2018
28	Single-institution experience of intensity-modulated radiotherapy for malignant pleural mesothelioma at University of Catania. ( 29400553 )	Spatola C....Privitera G.	2018
29	Bromodomain inhibition exerts its therapeutic potential in malignant pleural mesothelioma by promoting immunogenic cell death and changing the tumor immune-environment. ( 29399399 )	Riganti C....Taulli R.	2018
30	Increased sensitivity to apoptosis upon endoplasmic reticulum stress-induced activation of the unfolded protein response in chemotherapy-resistant malignant pleural mesothelioma. ( 29921948 )		2018
31	Is there a role for immunotherapy in malignant pleural mesothelioma? ( 29845408 )		2018
32	Revised Modified RECIST Criteria in Malignant Pleural Mesothelioma (Version 1.1): A Step Forward in a Long Race. ( 29935841 )		2018
33	Breast Metastasis from Malignant Pleural Mesothelioma: A Rare Challenging Entity. ( 29935848 )		2018
34	Is Pleurectomy/Decortication Superior to Extrapleural Pneumonectomy for Patients with Malignant Pleural Mesothelioma? A Single-Institutional Experience. ( 29367501 )		2018
35	Ipilimumab/Nivolumab-related Opsoclonus-Myoclonus-Ataxia Syndrome Variant in a Patient with Malignant Pleural Mesothelioma. ( 29742520 )		2018
36	Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. ( 29804728 )		2018
37	Proton beam therapy for malignant pleural mesothelioma. ( 29876318 )		2018
38	Malignant Pleural Mesothelioma presenting with Cardiac Tamponade- A Rare Case report and Review of the literature. ( 30294454 )	Jayaranagaiah A...McFarlane SI	2018
39	A single centre phase II trial to assess the immunological activity of TroVax® plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma - the SKOPOS trial. ( 30524880 )	Lester JF...Griffiths GO	2018
40	Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. ( 30524884 )	Noordam L...Vroman H	2018
41	Clustering of malignant pleural mesothelioma in asbestos factories: a subgroup analysis in a 29-year follow-up study to identify high-risk industries in Taiwan. ( 30530573 )	Lee LJ...Wang JD	2018
42	Combined modality treatment for malignant pleural mesothelioma: a single-centre long-term survival analysis using extrapleural pneumonectomy. ( 30535191 )	Frick AE...Nafteux P	2018
43	The FAK inhibitor BI 853520 inhibits spheroid formation and orthotopic tumor growth in malignant pleural mesothelioma. ( 30539198 )	Laszlo V...Hegedus B	2018
44	BAP1 gene mutations in Egyptian patients with advanced sporadic malignant pleural mesothelioma (MPM): relation with clinical outcomes and survival. ( 30553477 )	Bahnasy AA...Bastawisy AE	2018
45	Updates in the diagnosis and treatment of malignant pleural mesothelioma. ( 29553973 )	Katzman D...Sterman DH	2018
46	Inhibition of yes-associated protein down-regulates PD-L1 (CD274) expression in human malignant pleural mesothelioma. ( 29575535 )	Hsu PC...You L	2018
47	National Cancer Database Report on Pneumonectomy Versus Lung-Sparing Surgery for Malignant Pleural Mesothelioma. ( 29576300 )	Abdelsattar ZM...Blackmon SH	2018
48	Quality of life of survivors of malignant pleural mesothelioma in Japan: a cross sectional study. ( 29587685 )	Nagamatsu Y...Fujimoto N	2018
49	SYSTEMS-2: A randomised phase II study of radiotherapy dose escalation for pain control in malignant pleural mesothelioma. ( 29594241 )	Ashton M...Chalmers AJ	2018
50	Heterogeneity in Immune Cell Content in Malignant Pleural Mesothelioma. ( 29601534 )	Minnema-Luiting J...Cornelissen R	2018

Sources

Genes for Malignant Pleural Mesothelioma

Genes related to Malignant Pleural Mesothelioma (0 elite genes):

(show all 22)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubmedIds
1	PVT1	Pvt1 Oncogene	RNA Gene	160.15	Experimental evidence: Regulation ³⁹ DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)	24926545
2	GAS5	Growth Arrest Specific 5	RNA Gene	156.87	Experimental evidence: Regulation ³⁹ GeneCards inferred via : Publications (show sections)	24885398
3	ENSG00000261211		RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
4	ENSG00000258561		RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
5	LINC00535	Long Intergenic Non-Protein Coding RNA 535	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
6	POT1-AS1	POT1 Antisense RNA 1	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
7	SNHG7	Small Nucleolar RNA Host Gene 7	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
8	SNHG8	Small Nucleolar RNA Host Gene 8	RNA Gene	150	Experimental evidence: Regulation ³⁹	23976967
9	SPP1	Secreted Phosphoprotein 1	Protein Coding	30.73	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17493236 19528482 17504993 (more) 16221779 18550471 16911785 19634115 18670302
10	TYMS	Thymidylate Synthetase	Protein Coding	29.28	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	20177021 17333344
11	NKX2-1	NK2 Homeobox 1	Protein Coding	28.91	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	15614737 11234300 17279584 (more) 9500194 16415794 19152187 18051806 10757409 11956814
12	THBD	Thrombomodulin	Protein Coding	28.15	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9253621 1357974 10697265 (more) 9414183 12383211 19152187
13	BIRC5	Baculoviral IAP Repeat Containing 5	Protein Coding	28.06	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	12479365 18827603
14	WT1	Wilms Tumor 1	Protein Coding	27.93	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19516197 10759948 16415794 (more) 10757409 19152187
15	MSLN	Mesothelin	Protein Coding	26.57	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	19201924 16415794 18670302 (more) 18394747 20075387 17504993 17646232 19302997
16	XIAP	X-Linked Inhibitor Of Apoptosis	Protein Coding	24.51	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	17350081
17	MET	MET Proto-Oncogene, Receptor Tyrosine Kinase	Protein Coding	24.42	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	9692834
18	CALB2	Calbindin 2	Protein Coding	24.17	DISEASES inferred ¹⁵ Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	10697265 17279584 9796717 (more) 10595711 10759948 15736446 19152187 14976533 18051806 12383211 16415794
19	BAP1	BRCA1 Associated Protein 1	Protein Coding	24.16	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
20	MUC1	Mucin 1, Cell Surface Associated	Protein Coding	23.9	Novoseek inferred ⁵⁵ GeneCards inferred via : Publications (show sections)	2328062 9639123 12940775
21	EFEMP1	EGF Containing Fibulin Extracellular Matrix Protein 1	Protein Coding	23.44	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)
22	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	23.15	DISEASES inferred ¹⁵ GeneCards inferred via : Publications (show sections)

Sources

Variations for Malignant Pleural Mesothelioma

Copy number variations for Malignant Pleural Mesothelioma from CNVD:

⁷ (show all 35)

#	CNVD ID	Chromosom	Start	End	Type	Gene Symbol	CNVD Disease
1	13406	1	1	2300000	Loss		Pleural malignant mesothelioma
2	21839	1	16200000	28000000	Loss		Pleural malignant mesothelioma
3	33951	1	50700000	61300000	Amplification		Pleural malignant mesothelioma
4	35953	1	69700000	116100000	Loss		Pleural malignant mesothelioma
5	35955	1	69700000	116100000	Loss	CLCA1	Pleural malignant mesothelioma
6	35957	1	69700000	116100000	Loss	CLCA2	Pleural malignant mesothelioma
7	35959	1	69700000	116100000	Loss	CLCA3	Pleural malignant mesothelioma
8	35961	1	69700000	116100000	Loss	CLCA4	Pleural malignant mesothelioma
9	35963	1	69700000	116100000	Loss	COL11A1	Pleural malignant mesothelioma
10	35965	1	69700000	116100000	Loss	TGFBR3	Pleural malignant mesothelioma
11	35967	1	69700000	120600000	Loss		Pleural malignant mesothelioma
12	37057	1	84900000	107200000	Loss		Pleural malignant mesothelioma
13	69953	12	56600000	58100000	Gain		Pleural malignant mesothelioma
14	75173	13	17900000	45800000	Loss	BRCA2	Pleural malignant mesothelioma
15	85739	14	50900000	107349540	Loss	CCNK	Pleural malignant mesothelioma
16	85741	14	50900000	107349540	Loss	CDKN3	Pleural malignant mesothelioma
17	113646	17	44900000	81195210	Gain	ERN1	Pleural malignant mesothelioma
18	113648	17	44900000	81195210	Gain	MAP3K3	Pleural malignant mesothelioma
19	113650	17	44900000	81195210	Gain	PRKCA	Pleural malignant mesothelioma
20	113652	17	44900000	81195210	Gain	SMARCD2	Pleural malignant mesothelioma
21	175423	3	39400000	63700000	Loss	CACNA2D3	Pleural malignant mesothelioma
22	175425	3	39400000	63700000	Loss	CTNNB1	Pleural malignant mesothelioma
23	175427	3	39400000	63700000	Loss	MLH1	Pleural malignant mesothelioma
24	175772	3	44100000	44200000	Loss		Pleural malignant mesothelioma
25	187515	4	50400000	191154276	Loss		Pleural malignant mesothelioma
26	191706	5	1	48400000	Gain		Pleural malignant mesothelioma
27	204730	6	114600000	118300000	Loss	HDAC2	Pleural malignant mesothelioma
28	204732	6	114600000	118300000	Loss	MARCKS	Pleural malignant mesothelioma
29	217076	7	1	4500000	Gain		Pleural malignant mesothelioma
30	234872	8	139900000	146364022	Gain		Pleural malignant mesothelioma
31	250027	9	19900000	25600000	Loss	C9orf14	Pleural malignant mesothelioma
32	250030	9	19900000	25600000	Loss	CDKN2A	Pleural malignant mesothelioma
33	250032	9	19900000	25600000	Loss	CDKN2B	Pleural malignant mesothelioma
34	250070	9	19900000	33200000	Loss		Pleural malignant mesothelioma
35	251885	9	33200000	36300000	Gain		Pleural malignant mesothelioma

Sources

Expression for Malignant Pleural Mesothelioma

Search GEO for disease gene expression data for Malignant Pleural Mesothelioma.

Sources

Pathways for Malignant Pleural Mesothelioma

Sources

GO Terms for Malignant Pleural Mesothelioma

Sources

Sources for Malignant Pleural Mesothelioma

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia